Immunovant, Inc.
- IMVT · Nasdaq
- Biological Products, (No Diagnostic Substances)
- Durham, NC
- 315 employees
- CIK 0001764013
Updated from SEC filings through
Top things to know
Executives
-
Eric Venker Chief Executive Officer Form 4, July 6, 2026 - Tiago Girao Chief Financial Officer Form 4, July 24, 2026
- Tuyl Christopher Van Chief Legal Officer Form 4, September 25, 2026
-
Melanie Gloria Chief Operating Officer Form 4, August 21, 2026 - Jay S. Stout Chief Technology Officer Form 4, July 24, 2026
- Michael Geffner Chief Medical Officer Form 4, October 24, 2025
Immunovant, Inc. is a U.S. public company in biological products, (no diagnostic substances) (SIC 2836), headquartered in Durham, NC. It trades as IMVT on Nasdaq. It reported about 315 employees. Eric Venker is Chief Executive Officer.
Five-year financials
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | Not on file | Not on file | Not on file | Not on file | Not on file |
| Operating income | Not on file | Not on file | Not on file | Not on file | Not on file |
| SG&A | $76.2M 10-K, 2026-05-20 | $77.2M 10-K, 2026-05-20 | $57.3M 10-K, 2026-05-20 | $48.0M 10-K, 2025-05-29 | $54.2M 10-K, 2023-05-22 |
| Net income | -$506M 10-K, 2026-05-20 | -$414M 10-K, 2026-05-20 | -$259M 10-K, 2026-05-20 | -$211M 10-K, 2025-05-29 | -$157M 10-K, 2023-05-22 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Eric Venker, M.D., Pharm.D. | Named in proxy bio: Chief Executive Officer | DEF 14A, July 22, 2026 |
| | Chief Executive Officer | Form 4, July 6, 2026 |
| Tiago Girao | Chief Financial Officer | Form 4, July 24, 2026 |
| Tuyl Christopher Van | Chief Legal Officer | Form 4, September 25, 2026 |
| Chief Operating Officer | Chief Operating Officer | Form 4, August 21, 2026 |
| Jay S. Stout Chief Technology Officer at Immunovant | Chief Technology Officer | Form 4, July 24, 2026 |
| | Named in proxy bio: Chief Legal Officer and Corporate Secretary | DEF 14A, July 22, 2026 |
| Michael Geffner | Chief Medical Officer | Form 4, October 24, 2025 |
| Frank Torti | Board member (per proxy) bio: Director | DEF 14A, July 22, 2026 |
| Andrew Fromkin | Director | 10-K, May 20, 2026 |
| Atul Pande | Director | 10-K, May 20, 2026 |
| Douglas Hughes | Director | 10-K, May 20, 2026 |
| Jacob Bauer | Director | 10-K, May 20, 2026 |
| Robert Susman | Director | 10-K, May 20, 2026 |
What Immunovant, Inc. does
Immunovant, Inc. (“Immunovant,” “we” or the “Company”) is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Our focus is on developing IMVT-1402 (imeroprubart), a potentially best-in-class inhibitor of the neonatal fragment crystallizable receptor (“FcRn”), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (“IgG”) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies.
Shares and governance
| Shares outstanding | 206.9 million (as of November 3, 2026) | 10-Q, November 9, 2026 |
|---|---|---|
| Public float | $1.3B (as of September 30, 2025) | 10-K, May 20, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 9, 2026 |
| Latest proxy statement | Meeting September 2, 2026 (filed July 22, 2026) | DEF 14A, July 22, 2026 |
| Auditor | Ernst & Young LLP (Iselin, New Jersey) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| November 11, 2026 | Atul Pande Director | Sale | 3,000 | $108K | Form 4, November 12, 2026 |
| October 28, 2026 | Tiago Girao Chief Financial Officer | Sale | 6,606 | $188K | Form 4, October 30, 2026 |
| October 21, 2026 | Jay S. Stout Chief Technology Officer | Sale | 2,595 | $75K | Form 4, October 23, 2026 |
| October 7, 2026 | Tuyl Christopher Van Chief Legal Officer | Sale | 1,327 | $43K | Form 4, October 9, 2026 |
| October 7, 2026 | Melanie Gloria Chief Operating Officer | Sale | 2,241 | $72K | Form 4, October 9, 2026 |
| October 7, 2026 | Jay S. Stout Chief Technology Officer | Sale | 3,809 | $122K | Form 4, October 9, 2026 |
| October 2, 2026 | Eric Venker Chief Executive Officer | Sale | 3,506 | $120K | Form 4, October 5, 2026 |
| September 23, 2026 | Tuyl Christopher Van Chief Legal Officer | Sale | 2,846 | $103K | Form 4, September 25, 2026 |
Recent 8-K events
- 8-K filed 2026-11-09
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-09-03
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-08-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-05-20
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-02-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-12-12
- Item 8.01 Other events
- 8-K filed 2025-12-11
- Item 8.01 Other events
- 8-K filed 2025-11-21
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2025-11-10
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-09-03
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
Frequently asked questions about Immunovant, Inc.
- What does Immunovant, Inc. do?
- In its own words, from Item 1 of its 10-K: "Immunovant, Inc. (“Immunovant,” “we” or the “Company”) is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Our focus is on developing IMVT-1402 (imeroprubart), a potentially best-in-class inhibitor of the neonatal fragment crystallizable receptor (“FcRn”), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (“IgG”) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies."
- How many employees does Immunovant, Inc. have?
- About 315 as of March 31, 2026, as stated in its annual report.
- Who is the CEO of Immunovant, Inc.?
- Eric Venker, Chief Executive Officer, as named in a 4 filed July 6, 2026.
- Who is the CFO of Immunovant, Inc.?
- Tiago Girao, Chief Financial Officer, as named in a 4 filed July 24, 2026.
- Where is Immunovant, Inc. headquartered?
- Durham, NC.
- What is Immunovant, Inc.'s stock ticker?
- IMVT on Nasdaq.
- What industry is Immunovant, Inc. in?
- Biological Products, (No Diagnostic Substances), SIC code 2836.
- What is Immunovant, Inc.'s website?
- immunovant.com.
- When does Immunovant, Inc. report earnings next?
- February 8, 2027. This is an estimate from past filing dates, not a confirmed date.
- Is Immunovant, Inc. a public company?
- Yes. Immunovant, Inc. files with the SEC under CIK 0001764013 and trades as IMVT.
- Who audits Immunovant, Inc.?
- Ernst & Young LLP, Iselin, New Jersey, as named in its latest annual report (10-K).
- How many shares of Immunovant, Inc. are outstanding?
- 206.9 million shares as of November 3, 2026, from its 10-Q filed November 9, 2026.
- What is Immunovant, Inc.'s public float?
- $1.3B as of September 30, 2025, as reported on the cover of its 10-K filed May 20, 2026.
- How many business segments does Immunovant, Inc. report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 9, 2026.
- When is Immunovant, Inc.'s annual shareholder meeting?
- September 2, 2026, per its proxy statement (DEF 14A) filed July 22, 2026.
- Have Immunovant, Inc. insiders traded stock recently?
- Since July 9, 2025, officers and directors reported 50 open-market sales worth about $16.9M and 1 purchase worth about $350M on Forms 4 and 5. The most recent: Atul Pande (Director) sold 3,000 shares on November 11, 2026.